Portfolio and pipeline
Multiparticulate pellet formulations.
Semi-finished, ready-to-fill pellet dosage forms. Search by molecule, or separate commercial manufacture from the development pipeline.
Loading the portfolio…
Portfolio and pipeline
Semi-finished, ready-to-fill pellet dosage forms. Search by molecule, or separate commercial manufacture from the development pipeline.
Loading the portfolio…
Showing 8 validated formulations
Active Molecule: Domperidone
Sustained-release multiparticulates coated with a functional diffusion membrane to achieve extended drug release across gastrointestinal transit.
Validated drug load
30.0% w/w
Standards: IP · USP · BP
Active Molecule: Tamsulosin Hydrochloride
Micro-dose sustained release multiparticulates with membrane diffusion coating under development pipeline.
Validated drug load
0.2%, 0.4%, 0.12% & 0.16% w/w
Standards: IP / USP Candidate
Active Molecule: Venlafaxine Hydrochloride
Extended release multiparticulates utilizing membrane diffusion barriers under development pipeline.
Validated drug load
32.0%, 33.0%, 36.0% & 40.0% w/w
Standards: USP / IP Candidate
Active Molecule: Itopride Hydrochloride
Sustained release pellets under development pipeline.
Validated drug load
60.0% w/w
Standards: In-house Specification
Active Molecule: Diclofenac Sodium
Sustained release multiparticulate pellets with diffusion barrier coating under development pipeline.
Validated drug load
35.0%, 40.0% & 50.0% w/w
Standards: IP / BP Candidate
Active Molecule: Mebeverine Hydrochloride
Sustained release pellets with diffusion barrier coating under development pipeline.
Validated drug load
40.0%, 50.0% & 80.0% w/w
Standards: BP / IP Candidate
Active Molecule: Ketoprofen
Sustained-release NSAID multiparticulates under development pipeline.
Validated drug load
60.0% w/w
Standards: BP / IP Candidate
Active Molecule: Levosulpiride
Sustained release pellets under development pipeline for gastrointestinal motility blends.
Validated drug load
40.0% w/w
Standards: In-house Specification